Checkmate Pharmaceuticals, Inc.
CMPIDelisted May 31, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001651431
Checkmate Pharmaceuticals, Inc. was delisted on May 31, 2022; its insiders filed their last Form 4 on May 31, 2022; 26 institutions reported holding it in 13F filings for Q1 2022, worth $54.8M in total; no superinvestor held it.
Q4 2021 vs. Q3 2021
How the institutions holding Checkmate Pharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 32 | 25 | −7 |
| Shares | 16.4M | 16.1M | −222.4K (−1.4%) |
| Value | $64.5M | $46.3M | −$18.2M (−28.2%) |
New holders (1)
Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 10,633 | $31.0K | 0.00% |
Sold out (8)
Institutions that held Checkmate Pharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Jacobs Levy Equity Management, Inc | 36,511 | $145.0K |
| Ergoteles LLC | 25,870 | $103.0K |
| HRT Financial LP | 18,298 | $72.0K |
| Renaissance Technologies LLC | 10,667 | $42.0K |
| The PNC Financial Services Group, Inc. | 5,000 | $20.0K |
| Tower Research Capital LLC (TRC) | 1,426 | $6.00K |
| JPMorgan Chase & Co | 185 | $1.00K |
| Hall Laurie J Trustee | 100,530 | $0 |